¶ Early Detection and Preclinical Alzheimer's Disease at AAIC 2026
AAIC 2026 showcased significant advances in early detection of Alzheimer's disease (AD), focusing on identifying pathological changes before clinical symptoms emerge. The shift toward preclinical intervention represents a fundamental change in AD research and clinical practice.
The preclinical AD framework continues to evolve:
- Stage 1: Amyloid positivity without neurodegeneration or cognitive impairment
- Stage 2: Amyloid + neurodegeneration (AD signature region atrophy, FDG hypometabolism, or tau PET positivity)
- Stage 3: Amyloid + neurodegeneration + subtle cognitive changes
New integrated biomarker approaches:
- AT(N) classification: Amyloid (A), Tau (T), Neurodegeneration (N)
- Blood-based biomarkers: Adding AT(Blood) to the framework
- Dynamic biomarkers: Rate of change as predictive markers
Advances in blood biomarker implementation:
- Primary care integration: Feasibility studies in community settings
- At-risk populations: Screening in individuals with family history, cardiovascular disease, or diabetes
- Cost-effectiveness: Modeling for population screening programs
Practical considerations discussed at AAIC 2026:
- Assay standardization across laboratories
- Cut-point determination for clinical use
- Disclosure protocols for positive results
Single-molecule array (Simoa) and other ultrasensitive platforms:
- Detecting amyloid-beta at concentrations 100x lower than standard assays
- p-Tau217 elevation in cognitively normal individuals with amyloid positivity
- GFAP as early marker of astrocyte reactivity
Combining blood biomarkers with other assessments:
- Blood + genetic testing (APOE genotyping)
- Blood + digital biomarkers
- Blood + brief cognitive assessments
Detecting earliest cognitive manifestations:
- Preclinical Cognitive Impairment: Deficits detectable with sensitive neuropsychological tests
- Objective Subtle Cognitive Difficulties (Obj-SCD): Validated assessment approaches
- Cognitive reserve effects: Understanding resilience to pathology
Technology-enabled cognitive assessment:
- Smartphone-based cognitive testing
- Wearable sensor data for behavioral changes
- Voice analysis for language alterations
Utilizing PET for early detection:
- Centiloid scale standardization
- Low-dose protocols for screening
- Visual read standardization
Early tau detection advances:
- p-Tau231 as preclinical marker
- Entorhinal cortex tau as earliest detectable pathology
- Tau spreading patterns in preclinical stages
Structural MRI in preclinical AD:
- Hippocampal atrophy rates
- Default mode network connectivity changes
- White matter microstructural changes
Polygenic risk scores for AD:
- Combined APOE and non-APOE genetic variants
- Risk stratification for prevention trials
- Interaction with lifestyle factors
Integrating multiple risk factors:
- Demographic (age, sex, education)
- Genetic (APOE, polygenic risk)
- Biomarker (fluid, imaging)
- Lifestyle (physical activity, diet, cardiovascular)
Recruitment for preclinical AD trials:
- Blood biomarker-based screening efficiency
- Family history enrichment strategies
- Diverse population recruitment
Trials targeting amyloid removal in preclinical populations:
- Anti-amyloid antibodies in cognitively normal amyloid-positive individuals
- Outcome measures for prevention trials
- Ethical considerations in presymptomatic intervention
Recent revisions to AD diagnostic criteria:
- NIA-AA criteria for preclinical AD
- IWG criteria for presymptomatic AD
- Implementation in clinical practice
Recommendations for early detection:
- When to offer biomarker testing
- Counseling for individuals with preclinical AD
- Monitoring recommendations
Key areas for future research:
- Blood biomarker implementation: Standardization and accessibility
- Primary prevention: Initiating treatment before pathology accumulates
- Precision prevention: Tailored interventions based on individual risk profiles
- Global implementation: Adapting early detection for diverse populations
This page provides information about AAIC 2026: Early Detection and Preclinical AD.